Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track record of the firm behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 115,000 members, many of whom demonstrate better investing insight than published analysts do.
Enough top-performing CAPS investors have turned bullish on Allergan (NYSE: AGN ) recently to upgrade it from its four-star rank to a top-of-the-class five-stars. A total of 280 investors have given their opinion on Allergan, with many of them offering analysis and commentary explaining the recent optimism.
Botox maker Allergan has returned to its former glory, recapturing five-star status after dropping as low as three stars. Allergan’s long list of competitors includes Merck (NYSE: MRK ) , Pfizer (NYSE: PFE ) , and Johnson & Johnson (NYSE: JNJ ) , but the company has found a good niche in cosmetic drugs like Botox. Similar to Amgen's (Nasdaq: AMGN ) Epogen, Botox once started off with orphan drug designation, but now the wrinkle treatment is seeing strong adoption internationally. In the second quarter, Botox sales grew 13%, contributing to a 20% rise in revenue overall to $1.17 billion.
Recent forays into different sectors of the medical aesthetics market also have investors handicapping new revenue opportunities for Allergan. Eyeing the $3.7 billion mascara market dominated by the likes of Revlon and Estee Lauder (NYSE: EL ) , Allergan is developing a compound, bimatoprost, that will actually grow eyelashes longer. In a separate move, the company purchased the rights to QLT's (Nasdaq: QLTI ) acne drug Aczone for $150 million in cash, hoping to capture as much of the $800 million prescription acne treatment market as it can until the patents for Aczone start to expire in 2016. With new potential blockbuster treatments on the horizon, nearly 93% of the CAPS members rating Allergan expect it to outperform the market.